Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Hepatitis C, HIV Infections
Interventions: Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Cincinnati, Ohio • Richmond, Virginia

Conditions: Acute Mountain Sickness
Interventions: ambrisentan and theophylline, placebo; Drug
Lead sponsor: University of Montana; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Missoula, Montana

Conditions: Intradermal Electroporation
Interventions: EMLA Cream, Aveeno Daily Moist, Derma Vax, Intradermal Electroporation, Visual Analogue Scale, Present Pain Intensity, McGill Pain Questionnaire, Skin Assessment; Drug · Device · Procedure
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Interventions: CFI-400945, Azacitidine; Drug
Lead sponsor: Treadwell Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more

Conditions: Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer, Lung Cancer (NSCLC)
Interventions: KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy, Docetaxel; Biological · Drug
Lead sponsor: Krystal Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Dothan, Alabama • Scottsdale, Arizona • Beverly Hills, California + 11 more

Conditions: Nonmelanoma Skin Cancer, Basal Cell Carcinoma, Squamous Cell Carcinoma
Interventions: Vitamin D (VitD), Placebo, Photodynamic therapy (PDT), Mohs surgery or electrodessication & curettage (ED&C) (standard of care); Dietary Supplement · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Infections, Community Acquired Pneumonia
Interventions: Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Long Beach, California • Oakland, California • Orange, California + 10 more

Conditions: Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions: Autologous cultured dermal and epidermal cells; Biological
Lead sponsor: Aderans Research Institute; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Healthy Volunteer Study
Interventions: Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg dose administered fasting, Treatment C-Bemnifosbuvir/Ruzasvir FDC administered simultaneously with 20 mg dose of Omeprazole fasting, Treatment D-Bemnifosbuvir/Ruzasvir FDC administered 0.5 hour prior to 20 mg dose of Omeprazole, Treatment E-Omeprazole 40 mg administered fasting, Treatment F-Bemnifosbuvir/Ruzasvir FDC administered 2 hours after 40 mg dose Omeprazole; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Cypress, California

Conditions: HIV Infections
Interventions: Efavirenz, Lamivudine, Zidovudine; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 46
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
Interventions: Deferoxamine, Deferiprone (L1); Drug
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 6
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more

Conditions: Opiate Addiction, Refractory Pain
Interventions: buprenorphine/naloxone; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Lymphoma, Follicular
Interventions: Bortezomib, Rituximab, Fludarabine, Mitoxantrone, Dexamethasone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Total Ankle Arthroplasty, Postsurgical Analgesia
Interventions: EXPAREL, 0.25% bupivacaine (HCl): 50 ml, 0.25% bupivacaine (HCl): 30 ml; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Interventions: Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88; Drug
Lead sponsor: Pancreatic Cancer Action Network; Other
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 18 more

Conditions: HIV Infections
Interventions: Ribavirin, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • New Orleans, Louisiana + 7 more

Conditions: Pancreatic Cancer
Interventions: ABTL0812, Folfirinox, Placebo; Drug
Lead sponsor: Ability Pharmaceuticals SL; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Westwood, Kansas • Boston, Massachusetts + 1 more

Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Interventions: TL-895, Ruxolitinib; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Birmingham, Alabama • Canton, Ohio • Cincinnati, Ohio + 1 more

Conditions: Breast Cancer
Interventions: D-0502, palbociclib; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 11
States / cities: Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Heart Failure
Interventions: ACE inhibitor, Sacubitril/Valsartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 6,066 participants
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin
Interventions: MM-121, Docetaxel; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Tucson, Arizona • Los Angeles, California • Santa Rosa, California + 12 more

Conditions: Esophageal Cancer
Interventions: carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Ritonavir, Abacavir sulfate, Amprenavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 9 more

Conditions: Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Interventions: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution; Combination Product
Lead sponsor: Colorado Eye Consultants/Cornea Consultants of Colorado; Industry
Eligibility: 8 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio

Search by objective public record fields.

Effects of Anti-HIV Drugs on the Hepatitis C Virus (HCV) in Adults Infected With Both HCV and HIV

Drug Combination on Exercise Performance at High Altitude

Safety and Tolerability of the Derma Vax(Trademark) Clinical Intradermal Electroporation System in Healthy Subjects

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Vitamin D Effects on Immune Microenvironment of Nonmelanoma Skin Cancer After Photodynamic Therapy (PDT)

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Buprenorphine as a Treatment in Opiate Dependent Pain Patients

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Efficacy of EXPAREL vs. Bupivacaine

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

Safety and Effectiveness of the PXL-Platinum 330 System